People

Insys Therapeutics has announced that it will partner with Senzer Ltd, a subsidiary of Kind Consumer, to develop inhaled dronabinol (THC) and cannabidiol (CBD) products. Insys has licensed Senzer's delivery technology, the same technology in the Voke nicotine inhaler, which was approved in the UK in September 2014. Senzer CEO and Kind Consumer founder Alex Hearn … [Read more...] about Insys to develop inhaled cannabinoids using Voke inhaler technology, hires OINDP specialists

Cirrus Pharmaceuticals announced that it has hired Andrew Hamer as VP R&D. Hamer was most recently Senior Director of R&D Operations at GSK's dermatology subsidiary Stiefel. He also has experience in OINDP development at Cardinal, Sanofi, and Covance. Cirrus, based in Research Triangle Park, NC, was acquired by Kemwell in 2013. It offers inhalation and nasal … [Read more...] about Cirrus Pharmaceuticals hires Andrew Hamer as VP R&D

Intranasal analgesia developer Trigemina Inc. has announced the appointment of Shashidhar "Shashi" Kori as Chief Medical Officer. Trigemina's TI-114 intranasal oxytocin, is in Phase 2 development for the treatment of migraine headaches; the company is also developing an intranasal polypeptide for somatic pain. Kori was most recently Chief Medical officer at … [Read more...] about Trigemina names Shashi Kori as Chief Medical Officer

Moerae Matrix, which is developing inhaled therapies for the treatment of idiopathic pulmonary fibrosis and other lung diseases, has announced the appointment of Bill Bradford as Chief Medical Officer. Bradford was most recently a Senior Fellow at Intermune. Bradford commented, "I am excited to be joining Moerae at this important time in the company's evolution as … [Read more...] about Moerae Matrix hires Bill Bradford as Chief Medical Officer

Current AstraZeneca Vice President Respiratory, Inflammation & Autoimmunity James Ward-Lilley will become CEO of Vectura Group as of October 1 2015. Vectura had previously announced that its current CEO, Chris Blackwell, will be stepping down at the end of June 2015. Ward-Lilley, who has held a variety of roles at AstraZeneca over the past 28 years, commented, "I … [Read more...] about James Ward-Lilley to join Vectura as CEO

Turing Pharmaceuticals, which is developing intranasal oxytocin and ketamine products, has announced that it has hired Eliseo Oreste Salinas as President of Research and Development. Salinas was most recently President and Chief Scientific Officer of Relmada Therapeutics. According to the company, "He arrives as Turing prepares to begin clinical trials for several … [Read more...] about Turing Pharmaceuticals hires Eliseo Salinas as President of R&D

Inhaled drug developer Alexza Pharmaceuticals has announced the promotions of Edwin S. Kamemoto to Executive VP, R&D and Quality and Lori H. Takahashi to VP, Pharmaceutical R&D and Quality. Both positions are newly created. Kamemoto joined Alexza in 2006 and was most recently Senior VP, Regulatory Affairs. Takahashi joined Alexza in 2005 and most recently served as … [Read more...] about Alexza Pharmaceuticals announces promotions

Inhaled drug developer Aradigm has announced the appointment of Robert A. Reed as VP, Regulatory (CMC) and Quality. Reed was most recently Senior VP of CMC and Technical Operations at Celsion Corporation and has also previously held positions at XenoPort and Merck. Aradigm President and CEO Igor Gonda commented, “We are delighted that Dr. Reed has joined our team … [Read more...] about Aradigm appoints Robert A. Reed VP, Regulatory and Quality